Lipella Pharmaceuticals, Inc. · OTC:LIPO
Lipella Pharmaceuticals — Biotech Showcase 2023
16 slides from Lipella Pharmaceuticals's conference presentation, Jan 12, 2023
Slide 1: Liposomal Drug Delivery to Mucosal Surfaces
Liposomal Drug Delivery to Mucosal Surfaces Biotech Showcase 2023TM January 11, 2023 Wednesday, 2:00 PM ET Track: Yosemite A (Ballroom Level) (Nasdaq: LIPO) 1
Slide 2: Disclaimers: Forward-Looking Statements
2 Disclaimers Forward-Looking Statements The information in this presentation is being provided so you can familiarize yourself with Lipella Pharmaceuticals Inc. (together with its subsidiaries, “Lipella” the “Company,” “we,” “us,” or “our”) during this informational meeting. The presentation includ
Slide 3: Executive Summary
Executive Summary Emerging, clinical-stage, proprietary 505(b)(2) opportunity Overview of Opportunity LP-10 is a phase-2a, 505(b)(2) drug candidate for hemorrhagic cystitis A platform proprietary drug delivery technology optimized for use with epithelial tissue Issued patents in US, Canada, and Aust
Slide 4: Company History
Company History Born out of an NIH funded research collaboration on liposomal drug delivery to become a clinical-stage pharmaceutical company with a growing pipeline. 2005 2007 2008 2010 2019 2021 2021 2022 2012 2020 2021 2022 Platform patent awarded Jonathan Kaufman co-founds Lipella Michael Chance
Slide 5: Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss
Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss Hemorrhagic cystitis is a serious, life-threatening bladder damage from pelvic radiation therapy and/or bladder-toxic chemotherapy. Millions of patients are increasingly diagnosed with pelvic malignancies including prostate cancer, and cancers of
Slide 6: Cancer Survivorship & Hemorrhagic Cystitis
Prostate Cancer Cancer Survivorship & Hemorrhagic Cystitis Expected annual revenue per patient is $20,000 Market penetration of 60,000 patients (45%) yields $1.2 billion annual revenue The current phase-2a is focused on radiation cystitis. LP-10 is also expected to address hemorrhagic cystitis from
Slide 7: LP-10 for Hemorrhagic Cystitis
LP-10 for Hemorrhagic Cystitis LP-10 : Liposomal tacrolimus for hemorrhagic cystitis, phase-2a drug candidate Economics Indication Technology Platform technology Serious condition Large economics Serious and life threatening Orphan designation No adequate therapy High morbidity 505(b)(2) focus Lipos
Slide 8: LP-10 Stops Bleeding via Two Modes of Action
LP-10 Stops Bleeding via Two Modes of Action Tacrolimus’ molecular mechanism includes calmodulin mediated t-cell inhibition • LP-10 is a potent vasoconstrictor • reduces blood flow to the bladder lumen • LP-10 is a potent anti-inflammatory • Reduces tissue injury in the bladder Well-known pharmacolo
Slide 9: LP-10 Product Form
LP-10 Product Form Liposomal tacrolimus treatment for hemorrhagic cystitis Sterile powder Easy to deliver In-house CMC Low COGS 9 (Nasdaq: LIPO)
Slide 10: LP-10 Expected Regulatory Pathway
LP-10 Expected Regulatory Pathway Given the severity of the disease and the lack of adequate treatment, we anticipate that LP-10 will be a good candidate for multiple accelerated regulatory pathways. LP-10 Regulatory Pathway Reformulated generic with new IP Fast-track designation candidates Breakthr
Slide 11: LP-10: an Outstanding Drug Candidate
LP-10: an Outstanding Drug Candidate Multiple reasons increase LP-10 probability of success Well known mechanism of action Pre-clinical efficacy 505(b)(2) pathway FDA Orphan Designation US FDA IND approval Ongoing clinical evidence Potential $1.2 billion revenue Accelerated pathway candidate 11 (Nas
Slide 12: Asset Pipeline and LP-310
Asset Pipeline and LP-310 LP-310: Liposomal tacrolimus for oral lichen planus Oral rinse formulation of LP-10 Increased local concentration in oral cavity while minimalizing systemic toxicity 505(b)(2) pathway, platform technology expansion Low COGS and fast development plan Large market size opport
Slide 13: LP-10 Phase 2a Trial Design Summary
Key inclusion criteria: Key Exclusion criteria: LP-10 Phase 2a Trial Design Summary 13 1. Males and females, at least 18 years 2. History of sterile moderate to severe HC (Grades 2-4) for at least 3 months with at least 1 episode of hematuria with or without clot 3. Previous use of medications and/o
Slide 14: LP-10 Development Team
LP-10 Development Team LP-10 is developed by an experienced team with complementary skillset and years of experience working together. Jonathan Kaufman, PhD Michael Chancellor, MD Michele Gruber Janet Okonski Chief Executive Officer Chief Medical Officer Director of Operations Director Clinical Oper
Slide 15: Liposomal Drug Delivery to Mucosal Surfaces
Liposomal Drug Delivery to Mucosal Surfaces 15 (Nasdaq: LIPO)
Slide 16: Lipella Pharmaceuticals Inc.
16 Lipella Pharmaceuticals Inc. 7800 Susquehanna Street, Suite 505 Pittsburgh, PA 15208 412-894-1853 www.lipella.com (Nasdaq: LIPO)